2850189-48-7
Chemical Structure
DOTA-ECL1i
- CAS No.: 2850189-48-7
- Formula:C58H94N14O18S
- Molecular Weight:1307.51
InChIKey: MUIXJRGBNNZVEY-SQQUKPBYSA-N
SMILES: OC([C@@H](CSC(CC1=O)C(N1CCNC(CN2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)NC([C@@H](CCCCN)NC([C@@H](CC(C)C)NC([C@H](NC([C@@H]([C@@H](O)C)NC(CNC([C@H](N)CC(C)C)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O
Biological Activity: DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DOTA-ECL1i | 98.06% | DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
